Chris Schott

Eli Lilly & Co. (NYSE:LLY) may be down over 8% in the past month and nearly 5% over the past five days, but JPMorgan analyst Chris Schott isn't backing off. In fact, he's doubling down. Zepbound's Momentum Keeps Eli Lilly In The Lead With Zepbound continuing to dominate the GLP-1 obesity...

While there is increased visibility for Gilead Sciences, Inc’s (NASDAQ: GILD) HIV franchise, its emerging oncology franchise is not well reflected in its valuation, according to JPMorgan. The Gilead Sciences Analyst: Chris Schott upgraded the rating for Gilead Sciences from Neutral to...

Merck & Co., Inc.'s (NYSE: MRK) shares have underperformed the broader market and the pharma sector per se, and one among the two factors that have led to weakness is soft sales for its wonder cancer drug Keytruda in the fourth quarter. The Merck Analyst JPMorgan analyst Chris Schott...

It’s been a rough 2019 for some biotechs. Amneal Pharmaceuticals Inc (NYSE: AMRX) is down 81% year-to-date, while Teva Pharmaceutical Industries Ltd (NYSE: TEVA) is down 41%. JPMorgan sees redemption in one of the stocks — and further decline in the other. The Analyst Chris Schott...

Eli Lilly And Co (NYSE: LLY) is the best-positioned among large caps, given healthy core product growth, a growing portfolio of new launches and next-gen pipeline assets, potential for significant margin expansion and several sources of near- and long-term upside, according to JPMorgan. The Analyst...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA)'s third quarter earnings report disappointed investors, as it included another reduction to its full year 2017 earnings per share and revenue outlook. The Analyst JPMorgan's Chris Schott downgraded Teva's stock rating from Neutral...

As Valeant Pharmaceuticals Intl Inc (NYSE: VRX) shares continue to surge, JPMorgan analyst Chris Schott is not buying into the hype as he maintained his Neutral rating with a $10 price target. “Over the last two months, sentiment has become meaningfully less bearish following a series of...

This week, the FDA granted approval for Merck & Co., Inc. (NYSE: MRK)’s Keyruda for chemotherapy combination treatment of frontline lung cancer. While the approval was far from a surprise, it may be enough to move the needle for both Merck and rival Bristol-Myers Squibb Co (NYSE: BMY)....

JPMorgan said AbbVie Inc (NYSE: ABBV) should benefit from recent acquisitions as well as pipeline updates over the long term, despite downgrading the stock to Neutral from Overweight on valuation. "[G]iven the recent strength in shares, we believe AbbVie's profile is now better reflected at current...

JPMorgan has upgraded Eli Lilly and Co (NYSE: LLY) to Overweight from Neutral based on the potential for new product driven upside to estimates in 2017 and beyond. The brokerage's bullish thesis also reflects a favorable risk/reward for solanezumab data in Alzheimer patients late this year. Notably...

The road to a recovery for Valeant Pharmaceuticals Intl Inc (NYSE: VRX) seems long, while in the near term there are a number of uncertainties around the company’s business and cash flow trends, JPMorgan’s Chris Schott said in a report. He downgraded the rating for the company from...

Abstracts for the ASCO 2016 meeting were released on Wednesday evening. With the event only a couple of weeks away, JPMorgan analyst Chris Schott took a look at what investors can expect from the ASCO presentations of four big-name pharma companies. For Eli Lilly and Co (NYSE: LLY), ASCO will be...

JPMorgan has maintained its Overweight rating on Allergan plc Ordinary Shares (NYSE: AGN), saying that the double-digit growth in the company's brands business is expected to continue throughout the year. Allergan's first quarter adjusted earnings of $3.04 a share topped the Street's estimate of $3...

JPMorgan’s Chris Schott believes that Pfizer Inc. (NYSE: PFE) is well positioned in the currently volatile market due to its improving business fundamentals and attractive valuation and yield, which could provide a floor to the stock while the company mulls strategic opportunities. The...